<DOC>
	<DOCNO>NCT03079063</DOCNO>
	<brief_summary>The purpose multicentre , randomize , double blind , single dose , two-way cross-over study , compare pharmacokinetics ( PK ) biosimilar eptacog alfa ( activate ) Novoseven 24 patient , adult child ( &gt; 12 year ) , bleed , inherited coagulation factor VII ( FVII ) deficiency ( FVII &lt; 1 % ) . Patients randomize receive either single dose eptacog alfa biosimilar 30 μg/kg one single dose NovoSeven 30 μg/kg , vice versa , dos separate washout period . All patient follow 12 month receive biosimilar eptacog alfa , demand , every bleeding episode occur - - prophylaxis , aim monitoring inhibit antibody formation , lack efficacy collection safety data . Additional 26 patient inclusion exclusion criterion include study ( total 50 patient ) . These patient enter PK phase study follow receive biosimilar eptacog alfa , demand , every bleeding episode occur 12 month - - prophylaxis , aim monitoring inhibit antibody formation , lack efficacy collection safety data . The modality treatment biosimilar eptacog alfa ( demand prophylaxis ) decide Investigator .</brief_summary>
	<brief_title>Study Comparing Pharmacokinetic Biosimilar Eptacog Alfa With Novoseven® , Patients With Congenital Factor VII Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Factor VII Deficiency</mesh_term>
	<criteria>Patients confirm diagnosis congenital , severe Factor VII deficiency ( FVII &lt; 1 % ) , &gt; 2 episode bleeding/year require treatment FVII infusion , non bleed status . Patients Additional group immunogenicity enrol bleed episode require treatment FVII . Male female subject Adult child ( &gt; 12 year ) Written informed consent . For minor patient , parent/legal guardian provide consent , possible , patient assent also obtain . For compromised patient designate proxy must provide informed consent . Any type congenital acquire coagulopathy ( except congenital Factor VII deficiency ) , : liver disease ( hepatitis ) , vitamin k deficiency , uremia , malignancy . Antibodies Factor VII Patients enter PK Study Group suspend prophylactic regimen Novoseven AryoSeven ( biosimilar eptacog alfa ) 3 day start trial ( receive first dose study medication ) . Patients enter Additional Group Immunogenicity study , , expose AryoSeven start study [ patient receive Novoseven ( demand prophylaxis ) start study allow ] Platelet count le 100.000 platelets/μl ( screen visit ) Patients receive routine ( prophylactic ) treatment rFVIIa period screen visit ( visit 1 ) visit 2 study ( first dose administration ) Any clinical sign know history arterial thrombotic event deep venous thrombosis pulmonary embolism HIV positive current CD4+ count le 200/μl Liver Cirrhosis Known hypersensitivity study medication Parallel participation another experimental drug trial . Parallel participation another market drug trial may affect primary end point study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>